(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 May 2022 (27.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/109291 A1

(51) International Patent Classification:
C07K 16/10 (2006.01) *A61P 31/16* (2006.01)
A61K 39/395 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/US2021/060123

(22) International Filing Date:
19 November 2021 (19.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/117,437 23 November 2020 (23.11.2020) US
63/123,419 09 December 2020 (09.12.2020) US

(71) Applicants: **VIR BIOTECHNOLOGY, INC.** [US/US]; 499 Illinois Street, Suite 500, San Francisco, California 94158 (US). **HUMABS BIOMED SA** [CH/CH]; Via dei Gaggini 3, 6500 Bellinzona (CH).

(72) Inventors: **CORTI, Davide**; Via dei Gaggini 3, 6500 Bellinzona (CH). **PIZZUTO, Matteo Samuele**; Via dei Gaggini 3, 6500 Bellinzona (CH). **ZATTA, Fabrizia**; Via dei Gaggini 3, 6500 Bellinzona (CH). **CAMERONI, Elisabetta**; Via dei Gaggini 3, 6500 Bellinzona (CH). **SNELL, Gyorgy**; 499 Illinois Street, Suite 500, San Francisco, California 94158 (US).

(74) Agent: **MORGAN, John, A.** et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: ANTIBODIES AGAINST INFLUENZA A VIRUSES



Neutralizing activity of FHF11v9 vs FM08_MLNS against H1N1 and H3N2 viruses measured by IAV NP staining

FIG. 23

(57) Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to an influenza A virus hemagglutinin (HA) and can neutralize a IAV infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors that comprise such polynucleotides, host cells that can express the antibodies or antigen-binding fragments, related compositions, and methods of using the herein disclosed compositions to, for example, treat or prevent an IAV infection.

WO 2022/109291 A1

[Continued on next page]

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*